Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Personalised Activity Plan for BREAKing UP Sitting Time in Patients With Peripheral Arterial Disease and Intermittent Claudication (The BREAK UP Study) (BREAK UP)

keskiviikko 9. maaliskuuta 2022 päivittänyt: University of Leicester

Intermittent claudication is the most common manifestation of peripheral arterial disease, a common cardiovascular disease that causes blocked blood vessels (arteries) in the leg. Symptoms consist of persistent pain in one or both legs during exercise that is relieved with rest. Evidence suggests that high levels of uninterrupted sitting and sedentary behaviour are associated with cardiovascular disease risk, mortality and all-cause mortality. One of the main goals for treating people with intermittent claudication, is increased participation in physical activity. Supervised Exercise Programmes are recommended however these are not well tolerated and compliance is low. Alternative exercise, including short bouts of physical activity to break up sedentary time, has been suggested to help improve physical function.

This study will investigate whether alternative exercise, in the form of breaking up prolonged sitting time, will improve physical function in patients with intermittent claudication.

Patients will be screened during their routine clinic appointment at Glenfield Hospital. All other study activity will take place at the patients home.

Activity monitors will be worn for up to 8 days at baseline and follow-up, measuring step count and time, inactivity, activity time and intensity, and sleep duration. Participants will also be expected to wear activity monitors for the duration of the 8-week intervention to measure steps. Participants will be in the study for up to 18 weeks in total.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Due to COVID-19 restrictions, the BREAK UP study is being conducted as an 8-week home-based before and after intervention study with the aim to improve physical function measured via the WIQ; and to reduce sitting time by up to 60 minutes per day, seven days a week.

Participants will be required to make contact with members of the research team twice to complete assessments remotely, once to complete a coaching consultation, and once per week during the 8-week activity plan to discuss their performance. Organisation of these, and any contact associated with recruitment may require more frequent contact with the research team via telephone or email.

Contact 1 (Recruitment/ eligibility):

Expression of interest to participate will be sought by the treating clinician at Glenfield hospital (listed on the delegation log), who will offer the patient a Participant Information Sheet, contact details form to complete and a consent form. The patient may then be approached by a member of the research team to take their consent, having read the information sheet, or if the participant is happy to be, a member of the research team will contact them within two weeks via telephone and/or email the participant to discuss the study in more detail and determine if they wish to participate or not. After which, they will be asked to complete the consent form and post this back to the research team. Once the signed and dated consent forms have been received, the researcher can organise for the baseline data to be collected.

Contact 2 (Baseline assessments):

Within 2 weeks participants will be required to complete baseline assessments which includes information on their date of birth/age, sex, ethnicity, smoking status, alcohol consumption, medical history (co-morbidities) and a number of questionnaires to assess their quality of life, breathlessness, anxiety and depression, fatigue and physical function. These will be completed over the telephone with the researcher or the researcher will post the questionnaires to the participants which will need to be completed and returned by post. These assessments will take approximately 1 hour.

Participants will also be posted two activity monitors (monitor 1 and 2) one of which will be wrist worn and the other thigh worn, as well as information on how to fit these. Participants will wear these for a period of up to 8 days to collect habitual physical activity data. A daily sleep-wake log will be used to collect data on participants sleep and wake-time, which will be posted, along with instructions on how to complete these, and returned via post along with the activity monitors.

Contact 3 (Coaching consultation):

Within 2 weeks participants will receive a telephone or video call which will be termed a "coaching consult", during which fourteen 2-minute activities to break sitting time will be discussed with a member of the research team. Video tutorials and/or instruction cards of these activities will be sent via post prior to the coaching consult. These activities and data from the habitual physical activity measure will be used to inform personalised activity plans whereby participants will be encouraged, using Bandura's social cognitive theory, to use these activities to reduce sitting time by up to 60 minutes per day for 8-weeks. This contact will take approximately 15 minutes. The 8-week activity plan will be prescribed, to complete at home and will begin within 2 weeks of this contact.

Participants will wear a wrist-worn activity monitor for the duration of the home-based 8-week intervention (monitor 3). They will be instructed on how to use these during the coaching consultation and how to complete daily diaries for monitor wear and activity completion for the 8-week period.

During the 8-week intervention participants will be contacted once a week via telephone or video to discuss their performance on the activity plan and completion of the daily diary. This will take approximately 15 minutes a week. A member of the research team will organise this over email or telephone.

A second 8-day habitual physical activity measurement period will take place during week 8 of the intervention. Activity monitors 1 and 2 will be posted to participants in good time along with instructions on how to fit these. During this second habitual physical activity measurement period participants will continue to wear wrist-worn activity monitor 3 as well.

Contact 4 (Follow-up):

Participants will then be contacted for their final assessments within one week of the end of the 8-week intervention. The follow-up assessments will include the same assessments as at baseline, except for one questionnaire, and will be completed via telephone with a member of the research team, or a researcher will be post these out to the participant for completion. The assessments will take approximately 1 hour.

Opintotyyppi

Interventio

Ilmoittautuminen (Odotettu)

35

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Men and women
  • Age ≥18 years
  • ABPI <0.9 or >1.4 at rest OR >20% decrease post exercise. When ABPI is >0.9 but there is clinical suspicion of PAD, other non-invasive tests, which may include imaging, will be used to confirm diagnosis.
  • History of intermittent claudication (exercise induced, aching/cramping, pain affecting the lower limbs or buttocks, which subsides with rest)
  • Able and willing to give informed consent
  • Able to speak, read, and write English
  • Able to undertake light physical activity

Exclusion Criteria:

  • Individuals with type 1, gestational, or monogenic diabetes mellitus
  • On insulin therapy
  • Hospital admission in preceding 3 months
  • Current or planned pregnancy, or breast feeding
  • Contra-indications to exercise
  • Participation in CTIMP currently and/or in preceding 3 months
  • Already participating in a structured SEP
  • Serious illness with life-expectancy < 1 year
  • Previous major amputation
  • Recent cardiovascular event (within the last 12 months)
  • Comorbidity that the research team considered to be a contraindication to involvement in the study
  • Unable to communicate in English
  • Recent diagnosis or treatment for cancer (within 12 months)

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Experimental
Participants will take part in an 8-week home-based activity plan to break up sitting time by 60 minutes per day.
This research study aims to prove efficacy of a home-based physical activity intervention targeted at reducing periods of prolonged sitting and improving physical function in patients with intermittent claudication.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
To investigate overall changes in sitting time
Aikaikkuna: 8 weeks
Measured using accelerometers (comparison of time spent sitting at baseline vs. follow-up assessed via acceleration)
8 weeks
The walking impairment questionnaire
Aikaikkuna: 8 weeks
Total score for 16 questions measuring walking distance, speed and stair climbing from 0 (worst/inability) to 4 (best/without limitations)
8 weeks

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
To investigate overall changes in time spent performing physical activity
Aikaikkuna: 8 weeks
Measured using accelerometers (comparison of time spent performing physical activity at baseline vs. follow up assessed via mean acceleration mg/day )
8 weeks
To investigate overall changes in time spent in light physical activity
Aikaikkuna: 8 weeks
Measured using accelerometers (comparison of time spent in light physical activity at baseline vs. follow up assessed via acceleration mins/day)
8 weeks
To investigate overall changes in time spent in moderate physical activity
Aikaikkuna: 8 weeks
Measured using accelerometers (comparison of time spent in moderate physical activity at baseline vs. follow up assessed via acceleration mins/day)
8 weeks
To investigate overall changes in time spent in vigorous physical activity
Aikaikkuna: 8 weeks
Measured using accelerometers (comparison of time spent in vigorous physical activity at baseline vs. follow up assessed via acceleration mins/day)
8 weeks
To investigate overall changes in time spent in prolonged sitting
Aikaikkuna: 8 weeks
Measured using accelerometers (comparison of time spent sitting at baseline vs. follow-up assessed via acceleration)
8 weeks
To investigate overall changes in time spent in sleep
Aikaikkuna: 8 weeks
Measured using accelerometers (comparison of time spent sleeping at baseline vs. follow-up assessed via acceleration)
8 weeks
To investigate whether personalised activity breaks in sitting time improve quality of life
Aikaikkuna: 8 weeks
Measured using the Vascular Quality of Life (VascuQoL) questionnaire
8 weeks
To investigate whether personalised activity breaks in sitting time improve quality of life
Aikaikkuna: 8 weeks
Measured using the Euro Quality of Life (EQ-5D-5L) questionnaire
8 weeks
To investigate whether personalised activity breaks in sitting time improve breathlessness
Aikaikkuna: 8 weeks
Measured using the modified medical research council (mMRC) dyspnoea scale
8 weeks
To investigate whether personalised activity breaks in sitting time improve fatigue
Aikaikkuna: 8 weeks
Measured using Chalder's Fatigue Scale
8 weeks
To investigate whether personalised activity breaks in sitting time improve anxiety and depression
Aikaikkuna: 8 weeks
Measured using the hospital anxiety and depression scale
8 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 31. maaliskuuta 2021

Ensisijainen valmistuminen (Odotettu)

Lauantai 1. lokakuuta 2022

Opintojen valmistuminen (Odotettu)

Lauantai 1. lokakuuta 2022

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 14. syyskuuta 2020

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 30. syyskuuta 2020

Ensimmäinen Lähetetty (Todellinen)

Torstai 1. lokakuuta 2020

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 14. maaliskuuta 2022

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 9. maaliskuuta 2022

Viimeksi vahvistettu

Tiistai 1. maaliskuuta 2022

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

Once we have analysed the results, we will present our findings at scientific meetings and publish in medical research journals. All these results will be anonymous, and it would not be possible to identify participants.

IPD-jakamista tukeva tietotyyppi

  • STUDY_PROTOCOL
  • MAHLA
  • CSR

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa